Prolatan eye drops 0.005% bottle with dropper 2.5 ml

Prolatan eye drops are used for the following indications:

Composition

The active substance is latanoprost (1 ml of solution contains 0.05 mg of latanoprost).

Excipients: benzalkonium chloride, sodium chloride, sodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, water for injections.

Contraindication

Known hypersensitivity to any of the components that make up the drug.

Method of application

Recommended dose for adults, including the elderly

Recommended therapy: one drop in the affected eye once a day. The optimal effect is achieved when the drug is used in the evening.

The drug should not be used more often than once a day, as it has been shown that frequent use reduces the effectiveness of reducing intraocular pressure.

If a dose is missed, treatment should be continued by taking the same dose at the usual time. As with any eye drops, to reduce possible systemic absorption during instillation, it is recommended to press the lacrimal sac in the medial canthus of the eye for one minute (punctal occlusion). This should be done each time, immediately after instillation.

Contact lenses should be removed before instilling eye drops and can be reinserted after 15 minutes.

When using multiple topical ophthalmic agents other than latanoprost, they should be applied at least 5 minutes apart.

Children

The drug can be used in pediatric patients with the same dosage as for adults.

Data on the efficacy and safety of the drug in the age group up to one year are very limited (4 patients). There are no available data on the use in premature infants (born before 36 weeks of gestation).

In children aged birth to 3 years, who suffer mainly from primary congenital glaucoma, surgical intervention (e.g., trabeculotomy/goniotomy) remains the first-line treatment.

The safety of long-term use in children has not been established.

Application features

Pregnant women

The safety of this medicinal product for use in pregnant women has not been established. Its pharmacological action poses a potential risk to the course of pregnancy, to the fetus or newborn. Therefore, the drug should not be used during pregnancy.

Latanoprost and its metabolites may pass into breast milk, therefore, breastfeeding women should discontinue breastfeeding before treatment with the drug.

Latanoprost, according to animal studies, does not affect male or female fertility.

The physician should be informed immediately if the patient plans to become pregnant or thinks she is pregnant and is using latanoprost 0.005% eye drops, solution.

The drug should be used by women of reproductive age only under the supervision of a physician.

Drivers

As with other medications, instillation of eye drops may cause temporary blurred vision. Until this effect has passed, patients should not drive or operate complex machinery.

Overdose

Apart from eye irritation and conjunctival hyperemia, no other side effects on the eyes have been reported with an overdose of the drug.

Side effects

The majority of adverse events are related to the eyes. In an open-label 5-year study of latanoprost, 33% of patients experienced changes in iris pigmentation. Other ophthalmic side effects are usually transient and occur only with the use of the drug.

Storage conditions

Store at 2-8°C, protected from light and out of the reach of children.

Shelf life - 2 years.

After opening the bottle, store for no more than 4 weeks at a temperature not exceeding 25 °C.